Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Screening Peptide Binders to IL-17A Using Classical Molecular Dynamics

Created on 08 Sep 2026

Authors

Xu, W., Fu, W.

Abstract

Identifying short peptides that bind therapeutically relevant proteins is a practical step toward developing peptide-based inhibitors. Here we screened 64 tetrapeptides for binding to the IL-17A homodimer using classical all-atom molecular dynamics simulations (GROMACS 2022.2, FF19SB force field, TIP3P water, 200 ns production per complex). Binding was ranked by a composite score that combines short-range interaction energies (Coul-SR + LJ-SR), close-contact frequency, mean intermolecular distance, and hydrogen bond occupancy. The tetrapeptide LYS-THR-CYS-ASP achieved the highest score in the set (composite score 2.85, total interaction energy -556 kJ/mol, average 8.0 H-bonds). Across all 64 simulations, electrostatic interactions accounted for approximately 72% of the total interaction energy. Stronger binders tended to contain charged and polar residues (Asp, Glu, Cys, Arg, Thr), while weaker binders were enriched in hydrophobic residues. Contact analysis identified a recurring interaction surface on IL-17A centered on cysteine and aromatic residues (Chain A: CYS87, Chain B:CYS196, A:HIS86, B:TYR175, B:HIS195), which we describe as a cysteine-aromatic cradle. These results nominate LYS-THR-CYS-ASP as a candidate for experimental binding validation and suggest simple sequence guidelines for designing IL-17A-targeting peptides.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 08 Sep 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement